Cookie Policy

We've put some small files called essential cookies on your device to help our site work on your browser.
We also use analytical cookies to help up improve our website by collecting and reporting information on it's usage.

You can read more above this on our Privacy Policy page.

I'm ok with analytical cookies Do not use analytics cookies

Shield Reports on H1 Business Update

23 Jul 2018

Shield Therapeutics plc (LSE:STX), a commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients’ unmet medical needs, with an initial focus on addressing iron deficiency with its approved product, Feraccru®, today announces a business update following progress made in H1 2018.

Following the Company’s detailed analyses of the positive data from the placebo-controlled period of the AEGIS-CKD study, we completed a planned pre-NDA submission meeting with the FDA at which we presented the positive AEGIS-CKD study results together with a broader discussion regarding the Company’s intention to file an NDA for Feraccru in 2018.

You can read the full press release here.

Back to news